Announcements Trials
Browse Landscape

Phase

Phase NA 13Phase 2 9Phase EARLY_PHASE1 4Phase 1 4Phase 1/2 2Phase 4 1Phase 2/3 1

Status

Unknown 2Completed 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Head & Neck 1Genitourinary 1

Conditions

Breast Neoplasms 264Carcinoma, Non-Small-Cell Lung 219Neoplasms 218Leukemia, Myeloid, Acute 193Multiple Myeloma 178Colorectal Neoplasms 175Melanoma 165Prostatic Neoplasms 163Lymphoma 145Leukemia 142Lymphoma, Non-Hodgkin 133Glioblastoma 131Pancreatic Neoplasms 127Neoplasm Metastasis 118Lung Neoplasms 118Leukemia, Lymphocytic, Chronic, B-Cell 118Ovarian Neoplasms 112Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Recurrence 97Myelodysplastic Syndromes 93Hodgkin Disease 92Lymphoma, Large B-Cell, Diffuse 89Lymphoma, Follicular 89Lymphoma, Mantle-Cell 83Head and Neck Neoplasms 79Carcinoma, Renal Cell 79Brain Neoplasms 77Sarcoma 73Carcinoma, Hepatocellular 73Squamous Cell Carcinoma of Head and Neck 71

Interventions

fluoromisonidazole 1TH 302 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Hypoxia × Clear all
NCT00743379 2015-05-07

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1/2 Completed
71 enrolled
GastrointestinalGenitourinaryThoracic

Hypoxia, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01213030 2012-09-25

Clinical Evaluation of the New Hypoxia Imaging Agent HX4

Siemens Molecular Imaging

Phase 1/2 Completed
12 enrolled
GastrointestinalHead & NeckThoracic

Hypoxia, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡